JP7463351B2 - 脳卒中の血液バイオマーカー - Google Patents
脳卒中の血液バイオマーカー Download PDFInfo
- Publication number
- JP7463351B2 JP7463351B2 JP2021514483A JP2021514483A JP7463351B2 JP 7463351 B2 JP7463351 B2 JP 7463351B2 JP 2021514483 A JP2021514483 A JP 2021514483A JP 2021514483 A JP2021514483 A JP 2021514483A JP 7463351 B2 JP7463351 B2 JP 7463351B2
- Authority
- JP
- Japan
- Prior art keywords
- stroke
- signature
- subject
- sample
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims description 211
- 210000004369 blood Anatomy 0.000 title claims description 165
- 239000008280 blood Substances 0.000 title claims description 165
- 208000006011 Stroke Diseases 0.000 claims description 382
- 230000014509 gene expression Effects 0.000 claims description 225
- 238000000034 method Methods 0.000 claims description 138
- 210000004556 brain Anatomy 0.000 claims description 108
- 101001037968 Homo sapiens Heat shock 70 kDa protein 1B Proteins 0.000 claims description 105
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 claims description 102
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 claims description 98
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 claims description 98
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 98
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 97
- 101000893656 Homo sapiens G0/G1 switch protein 2 Proteins 0.000 claims description 96
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims description 96
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 claims description 95
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 claims description 95
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 claims description 95
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 94
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 claims description 93
- 102100040861 G0/G1 switch protein 2 Human genes 0.000 claims description 93
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 92
- 238000011282 treatment Methods 0.000 claims description 40
- 230000004044 response Effects 0.000 claims description 33
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 32
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 17
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 16
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 13
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 7
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 2
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims 6
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 claims 6
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 claims 6
- 102100026651 Pro-adrenomedullin Human genes 0.000 claims 6
- 239000000523 sample Substances 0.000 description 303
- 108090000623 proteins and genes Proteins 0.000 description 232
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 96
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 94
- 102000004379 Adrenomedullin Human genes 0.000 description 91
- 101800004616 Adrenomedullin Proteins 0.000 description 91
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 91
- -1 C-FOS Proteins 0.000 description 69
- 230000000302 ischemic effect Effects 0.000 description 68
- 210000001124 body fluid Anatomy 0.000 description 65
- 239000010839 body fluid Substances 0.000 description 62
- 208000028867 ischemia Diseases 0.000 description 30
- 241000282693 Cercopithecidae Species 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 206010008118 cerebral infarction Diseases 0.000 description 24
- 201000006474 Brain Ischemia Diseases 0.000 description 23
- 206010008120 Cerebral ischaemia Diseases 0.000 description 23
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 description 22
- 101001066163 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 gamma Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 238000002493 microarray Methods 0.000 description 21
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 description 20
- 102000054184 GADD45 Human genes 0.000 description 20
- 238000003384 imaging method Methods 0.000 description 20
- 238000004393 prognosis Methods 0.000 description 20
- 101710177131 Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 19
- 101000603399 Homo sapiens Neuronal PAS domain-containing protein 4 Proteins 0.000 description 19
- 108090001005 Interleukin-6 Proteins 0.000 description 19
- 102100038877 Neuronal PAS domain-containing protein 4 Human genes 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 238000002595 magnetic resonance imaging Methods 0.000 description 19
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 18
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 18
- 206010021143 Hypoxia Diseases 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102100029715 DnaJ homolog subfamily A member 4 Human genes 0.000 description 17
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 description 17
- 101150096895 HSPB1 gene Proteins 0.000 description 17
- 102100028829 Heat shock 70 kDa protein 4L Human genes 0.000 description 17
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 17
- 101000866014 Homo sapiens DnaJ homolog subfamily A member 4 Proteins 0.000 description 17
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 17
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 17
- 101001078634 Homo sapiens Heat shock 70 kDa protein 4L Proteins 0.000 description 17
- 206010061216 Infarction Diseases 0.000 description 17
- 241000282560 Macaca mulatta Species 0.000 description 17
- 238000002591 computed tomography Methods 0.000 description 17
- 230000007574 infarction Effects 0.000 description 17
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 16
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 description 16
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 16
- 102100023226 Early growth response protein 1 Human genes 0.000 description 16
- 102100021720 Early growth response protein 4 Human genes 0.000 description 16
- 102100025626 GTP-binding protein GEM Human genes 0.000 description 16
- 102100033962 GTP-binding protein RAD Human genes 0.000 description 16
- 102100028761 Heat shock 70 kDa protein 6 Human genes 0.000 description 16
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 16
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 16
- 101000896533 Homo sapiens Early growth response protein 4 Proteins 0.000 description 16
- 101000856606 Homo sapiens GTP-binding protein GEM Proteins 0.000 description 16
- 101001132495 Homo sapiens GTP-binding protein RAD Proteins 0.000 description 16
- 101001078680 Homo sapiens Heat shock 70 kDa protein 6 Proteins 0.000 description 16
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 16
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 16
- 101001096050 Homo sapiens Perilipin-2 Proteins 0.000 description 16
- 101000933604 Homo sapiens Protein BTG2 Proteins 0.000 description 16
- 101000843562 Homo sapiens Transcription factor HES-4 Proteins 0.000 description 16
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 16
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 16
- 102100037896 Perilipin-2 Human genes 0.000 description 16
- 102100026034 Protein BTG2 Human genes 0.000 description 16
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 description 16
- 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 description 16
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 16
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 16
- 102100030774 Transcription factor HES-4 Human genes 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000007954 hypoxia Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000005013 brain tissue Anatomy 0.000 description 14
- 238000010199 gene set enrichment analysis Methods 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000037361 pathway Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000013151 thrombectomy Methods 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241000288906 Primates Species 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010195 expression analysis Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 210000003657 middle cerebral artery Anatomy 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
- 241000282553 Macaca Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000004090 neuroprotective agent Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000002537 thrombolytic effect Effects 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 5
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002597 diffusion-weighted imaging Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000003938 response to stress Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 4
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 229960002078 sevoflurane Drugs 0.000 description 4
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 238000012049 whole transcriptome sequencing Methods 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229960001862 atracurium Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000009459 hedgehog signaling Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000019689 luncheon sausage Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011809 primate model Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 229960003766 thrombin (human) Drugs 0.000 description 3
- 229960000103 thrombolytic agent Drugs 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010047348 Vertigo positional Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000000691 benign paroxysmal positional nystagmus Diseases 0.000 description 2
- 208000001870 benign paroxysmal positional vertigo Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003788 cerebral perfusion Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002075 inversion recovery Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- BTIHMVBBUGXLCJ-HNNXBMFYSA-N (2s)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-HNNXBMFYSA-N 0.000 description 1
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 description 1
- UTBSBSOBZHXMHI-LSDHHAIUSA-N 2-n-[(1r,2s)-2-aminocyclohexyl]-6-n-(3-chlorophenyl)-9-ethylpurine-2,6-diamine Chemical compound N1=C(N[C@H]2[C@H](CCCC2)N)N=C2N(CC)C=NC2=C1NC1=CC=CC(Cl)=C1 UTBSBSOBZHXMHI-LSDHHAIUSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 102000009064 Antithrombin Proteins Human genes 0.000 description 1
- 108010049298 Antithrombin Proteins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000264368 Coptotermes lacteus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010038537 Dual Specificity Phosphatase 1 Proteins 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101150033270 Gadd45a gene Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000203367 Methanothermus fervidus Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 102100021494 Protein S100-P Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 241000042515 Tetraselmis rubens Species 0.000 description 1
- 241000191098 Thermoflexibacter ruber Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 208000005386 Transient Global Amnesia Diseases 0.000 description 1
- 208000008116 Traumatic Cerebral Hemorrhage Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000012152 algorithmic method Methods 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- FKQQKMGWCJGUCS-UHFFFAOYSA-N atromentin Chemical compound O=C1C(O)=C(C=2C=CC(O)=CC=2)C(=O)C(O)=C1C1=CC=C(O)C=C1 FKQQKMGWCJGUCS-UHFFFAOYSA-N 0.000 description 1
- AAEDGQBSNHENEM-UHFFFAOYSA-N atromentin Natural products OCC1(O)C2=C(C(=O)C(=C(C2=O)c3ccc(O)cc3)O)c4ccc(O)cc14 AAEDGQBSNHENEM-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 210000000275 circle of willis Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950001282 desmoteplase Drugs 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229940019332 direct factor xa inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003971 excitatory amino acid agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000010209 gene set analysis Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010005808 hementin Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002806 hypometabolic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960002268 triflusal Drugs 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024051056A JP2024075761A (ja) | 2018-05-16 | 2024-03-27 | 脳卒中の血液バイオマーカー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305600 | 2018-05-16 | ||
| EP18305600.1 | 2018-05-16 | ||
| PCT/EP2019/062653 WO2019219831A1 (en) | 2018-05-16 | 2019-05-16 | Blood biomarkers of stroke |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051056A Division JP2024075761A (ja) | 2018-05-16 | 2024-03-27 | 脳卒中の血液バイオマーカー |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523744A JP2021523744A (ja) | 2021-09-09 |
| JP2021523744A5 JP2021523744A5 (https=) | 2022-05-23 |
| JPWO2019219831A5 JPWO2019219831A5 (https=) | 2022-05-23 |
| JP7463351B2 true JP7463351B2 (ja) | 2024-04-08 |
Family
ID=62386311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514483A Active JP7463351B2 (ja) | 2018-05-16 | 2019-05-16 | 脳卒中の血液バイオマーカー |
| JP2024051056A Pending JP2024075761A (ja) | 2018-05-16 | 2024-03-27 | 脳卒中の血液バイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051056A Pending JP2024075761A (ja) | 2018-05-16 | 2024-03-27 | 脳卒中の血液バイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12247257B2 (https=) |
| EP (1) | EP3794355A1 (https=) |
| JP (2) | JP7463351B2 (https=) |
| KR (1) | KR20210049026A (https=) |
| CN (1) | CN112424609A (https=) |
| AU (1) | AU2019270404B2 (https=) |
| BR (1) | BR112020023259A2 (https=) |
| CA (1) | CA3100171A1 (https=) |
| IL (1) | IL278666B2 (https=) |
| MA (1) | MA52617A (https=) |
| MX (1) | MX2020012297A (https=) |
| SG (1) | SG11202011369VA (https=) |
| WO (1) | WO2019219831A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220093267A1 (en) * | 2019-01-22 | 2022-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Noninvasive real-time patient-specific assessment of stroke severity |
| CN114107487B (zh) * | 2021-12-23 | 2024-01-09 | 太原市精神病医院 | 一种可用于诊断脑卒中的产品 |
| JP2023111774A (ja) * | 2022-01-31 | 2023-08-10 | 国立研究開発法人国立循環器病研究センター | 再灌流療法の適用を決定するバイオマーカー |
| CN116705296B (zh) * | 2023-06-06 | 2024-09-13 | 中国科学院深圳先进技术研究院 | 一种基于常规mri序列对gbm患者进行风险分层的方法及系统 |
| WO2025151599A1 (en) * | 2024-01-09 | 2025-07-17 | Morehouse School Of Medicine | Rna-based method for stroke assessment and treatment |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015054700A2 (en) | 2013-10-13 | 2015-04-16 | The Research Foundation For Suny | Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof |
| JP2016507235A (ja) | 2013-02-01 | 2016-03-10 | ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ | 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法 |
| WO2017011329A1 (en) | 2015-07-10 | 2017-01-19 | West Virginia University | Markers of stroke and stroke severity |
| WO2018067571A2 (en) | 2016-10-03 | 2018-04-12 | West Virginia University | Computer implemented discovery of biomarkers for blood brain barrier disruption |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU2002241520A1 (en) * | 2000-11-28 | 2003-03-03 | University Of Cincinnati | Blood assessment of injury |
| US9005891B2 (en) | 2009-11-10 | 2015-04-14 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
| US9410204B2 (en) | 2012-01-07 | 2016-08-09 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| US20150274815A1 (en) * | 2012-09-25 | 2015-10-01 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Treatment of central nervous system (cns) injury |
-
2019
- 2019-05-16 SG SG11202011369VA patent/SG11202011369VA/en unknown
- 2019-05-16 EP EP19723441.2A patent/EP3794355A1/en active Pending
- 2019-05-16 CN CN201980047566.0A patent/CN112424609A/zh active Pending
- 2019-05-16 WO PCT/EP2019/062653 patent/WO2019219831A1/en not_active Ceased
- 2019-05-16 MX MX2020012297A patent/MX2020012297A/es unknown
- 2019-05-16 JP JP2021514483A patent/JP7463351B2/ja active Active
- 2019-05-16 KR KR1020207035973A patent/KR20210049026A/ko not_active Ceased
- 2019-05-16 BR BR112020023259-9A patent/BR112020023259A2/pt unknown
- 2019-05-16 MA MA052617A patent/MA52617A/fr unknown
- 2019-05-16 US US17/054,820 patent/US12247257B2/en active Active
- 2019-05-16 IL IL278666A patent/IL278666B2/en unknown
- 2019-05-16 CA CA3100171A patent/CA3100171A1/en active Pending
- 2019-05-16 AU AU2019270404A patent/AU2019270404B2/en active Active
-
2024
- 2024-03-27 JP JP2024051056A patent/JP2024075761A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016507235A (ja) | 2013-02-01 | 2016-03-10 | ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ | 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法 |
| WO2015054700A2 (en) | 2013-10-13 | 2015-04-16 | The Research Foundation For Suny | Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof |
| WO2017011329A1 (en) | 2015-07-10 | 2017-01-19 | West Virginia University | Markers of stroke and stroke severity |
| WO2018067571A2 (en) | 2016-10-03 | 2018-04-12 | West Virginia University | Computer implemented discovery of biomarkers for blood brain barrier disruption |
Non-Patent Citations (1)
| Title |
|---|
| Genomics，2014年，Vol. 104，pp. 163-169 |
Also Published As
| Publication number | Publication date |
|---|---|
| MA52617A (fr) | 2021-03-24 |
| KR20210049026A (ko) | 2021-05-04 |
| EP3794355A1 (en) | 2021-03-24 |
| AU2019270404B2 (en) | 2025-04-17 |
| SG11202011369VA (en) | 2020-12-30 |
| AU2019270404A2 (en) | 2020-12-17 |
| IL278666B1 (en) | 2025-02-01 |
| US20210214793A1 (en) | 2021-07-15 |
| JP2021523744A (ja) | 2021-09-09 |
| AU2019270404A1 (en) | 2020-12-10 |
| MX2020012297A (es) | 2021-03-25 |
| JP2024075761A (ja) | 2024-06-04 |
| IL278666A (en) | 2020-12-31 |
| BR112020023259A2 (pt) | 2021-02-23 |
| US12247257B2 (en) | 2025-03-11 |
| CA3100171A1 (en) | 2019-11-21 |
| WO2019219831A1 (en) | 2019-11-21 |
| IL278666B2 (en) | 2025-06-01 |
| CN112424609A (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7463351B2 (ja) | 脳卒中の血液バイオマーカー | |
| US20160265059A1 (en) | Biomarkers for diagnosis of stroke and its causes | |
| US10895572B2 (en) | Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients | |
| US20090208939A1 (en) | Identification of Molecular Diagnostic Markers for Endometriosis in Blood Lymphocytes | |
| JP2023501760A (ja) | 子癇前症に特異的な循環ｒｎａシグネチャー | |
| US20200188356A1 (en) | Novel Circular RNA Biomarkers for Heart Failure | |
| RU2821748C2 (ru) | Способы диагностики инсульта, эффективности терапии, определения риска инсульта | |
| US20210087634A1 (en) | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna | |
| CN108004316A (zh) | 用于预测急性心肌梗死风险的试剂盒 | |
| US20240125766A1 (en) | Method for determining suitability of a subject to anti tnf alpha therapy | |
| CA2960435C (en) | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna | |
| JP2024161911A (ja) | アトピー性皮膚炎の重症度の検出方法 | |
| WO2022186296A1 (ja) | アトピー性皮膚炎の症度悪化の検出方法 | |
| JP2022134127A (ja) | アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法 | |
| KR20130141044A (ko) | 급성 심근경색 조기 진단 마커 | |
| CN109971858A (zh) | 血管母细胞瘤复发跟踪诊断试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220513 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220513 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7463351 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |